Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/20/2025 | $45.00 | Buy | Craig Hallum |
12/5/2024 | $38.00 → $37.00 | Buy → Neutral | Goldman |
11/15/2024 | $50.00 | Outperform | Wolfe Research |
10/16/2024 | $43.00 | Buy | UBS |
10/10/2024 | $40.00 | Buy | Guggenheim |
2/23/2024 | $30.00 → $33.00 | Buy | Needham |
1/18/2023 | Outperform → Mkt Perform | Raymond James | |
1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with its Decipher Prostate and Decipher Bladder genomic classifiers will be presented at ASCO, the annual meeting of the American Society of Clinical Oncology, being held May 30-June 3 in Chicago. Key findings shed new light on which patients with prostate or bladder cancer may be more likely to respond to specific therapies based on their tumors' molecular make-up. "These new findings underscore the power of our whole-transcriptome-based Decipher GRID, or Genomic Resource for Intelligent Discovery, research tool to help advance understanding of
Veracyte, Inc. (NASDAQ:VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Blair 45th Annual Growth Stock Conference – Chicago, IL Presentation on June 3rd at 5:40 p.m. Eastern Time Jefferies Global Healthcare Conference – New York, NY Presentation on June 4th at 2:00 p.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast. About Veracyte Veracyte (NASDAQ:VCYT) is a global diagnostics company whose visi
Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)